To address this medical need, and as TCGA data indicated high expression of the target antigen CD276 on tumor cells, we here evaluated the efficacy of our bsAb CC-3 targeting CD276 and CD3 as treatment option for endometrial cancer. Here, CD276 is linked to endometrial cancer.